Delirium and other neurocognitive complications during COVID-19

Delirium during COVID-19

Abstract

As a result of COVID-19, morbidity and mortality rates continue to rise significantly throughout the world, including Puerto Rico. Although the predominant clinical presentation is a respiratory disease, SARS-CoV-2 can affect the central nervous system and cause neurocognitive manifestations, including delirium. Due to the hospital's organizational issues, the management of the disorder may be altered. Attention should be paid to this issue since delirium is associated with a worse prognosis and a higher mortality rate. It is also considered a vital sign that suggests worsening respiratory failure. For this reason, a standardized diagnostic approach should be enhanced. On the other hand, patients with Alzheimer's disease (AD) may be at greater risk of infection and mortality from COVID-19. This review aims to describe some contributing factors to delirium development, expected challenges in patients with AD, and possible long-term cognitive and psychological sequelae in patients recovered from the virus.